NUTRITIONAL STATUS AND DYSLIPIDEMIAS IN INSTITUTIONALIZED PATIENTS WITH ANTIRETROVIRAL TREATMENT FOR HIV/AIDS, FROM THE STATE OF HIDALGO, MEXICO

Background: Highly active antiretroviral therapy (HAART) has succeeded in increasing the survival of HIVpositive patients; however, its use is not exempt of adverse effects, one of them: dyslipidemias. Objective: The objective of this work was to describe nutritional status and prevalence of dyslipidemias in HIVinfected male patients who received HAART. Methods: 261 records of male patients between 25 to 44 years of age, attended at CAPASITS in Hidalgo, Mexico from 2009 to 2019, were reviewed. Lipid profile (total cholesterol, HDL, LDL and triglycerides), weight, height, viral load and CD4+ count, were recorded at the beginning and 6 months after starting HAART. Diagnoses of dyslipidemias were made using criteria of the Adult Treatment Panel III (ATP III). WHO BMI cut-off points were used to classify underweight, normal weight, overweight and obesity. Results: The average age of patients was 32.8 ± 5.3 years; the most frequent HAART, included a combination of nonnucleoside and nucleoside reverse transcriptase inhibitors. Initial and final mean of viral load and CD4+ count were 311,321 ±3.7 x104 vs. 13,512 ± 8.8 x103 copies and 244.7 ± 11.6 vs. 357.9 ± 15.3 cell/ml³, respectively. At 6 months with HAART, the percentage changes of abnormal numbers of triglycerides, total cholesterol, HDL and LDL were 14.2, 10.7, 16.8 and 17.5, respectively. Likewise, underweight, overweight and obesity had a percentage change of -6.1, 8.0 and 2.1, respectively. Conclusions: Six months after starting treatment, HAART significantly reduced the number of copies of the virus, with a negative effect on the prevalence of dyslipidemias, mostly LDL, followed by triglycerides.